Q1 2026 Q linea AB Earnings Call Transcript
Key Points
- Q-linea AB (FRA:3F80) achieved a record quarter for moving instruments into the market, deploying seven instruments.
- The company received FDA clearance for its V2 panel, significantly expanding its value proposition for U.S. customers.
- There was a 60% increase in consumable sales compared to the same quarter last year, indicating strong recurring income growth.
- Q-linea AB (FRA:3F80) successfully executed restructuring and cost management activities, reducing OpEx below 11 million SEK per month.
- The company is launching a dedicated isolate kit under research use-only registration in Q3 2026, expanding its product offerings.
- Net sales were lower than the same period last year due to reduced capital sales.
- The company faces challenges in converting its U.S. commercial pipeline, requiring significant effort to finalize contracts and installations.
- Economic constraints in Italy are causing rationing of rapid AST tests, limiting immediate growth potential in that market.
- The company is still working on securing financing for ASTAR placements, which is contingent on sales success.
- There are ongoing challenges in the collaboration with Blasted, particularly regarding the economic feasibility of a direct-from-whole-blood solution.
Welcome to the Q-Linea Q1 Report 2026. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Stuart Gander and CFO Krister Samuelson. Please go ahead.
Hello and welcome everyone to our presentation of our Q1 report. I know that we're going into a long weekend here in Sweden, so really appreciate everyone taking the time to join.
I'll start off with the usual disclaimer here. We'll take this as read and understood.
So we'll go through the fairly regular agenda we've done on these. I'll give you some of the commercial updates here. I'll speak to our recent FDA clearance and what that means for us in the market and for our customers. And then I'll spend a little bit of time on our priorities for the remainder of the year before handing over to Krister to go through the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
